Goldman Sachs’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $60.2M | Sell |
1,275,569
-17,039
| -1% | -$804K | 0.01% | 1028 |
|
|
2025
Q1 | $50.5M | Sell |
1,292,608
-382,056
| -23% | -$14.9M | 0.01% | 1050 |
|
|
2024
Q4 | $90.7M | Buy |
1,674,664
+178,833
| +12% | +$9.68M | 0.01% | 716 |
|
|
2024
Q3 | $75.4M | Buy |
1,495,831
+244,084
| +19% | +$12.3M | 0.01% | 809 |
|
|
2024
Q2 | $55M | Buy |
1,251,747
+1,093,587
| +691% | +$48.1M | 0.01% | 949 |
|
|
2024
Q1 | $7.94M | Buy |
158,160
+7,026
| +5% | +$353K | ﹤0.01% | 2238 |
|
|
2023
Q4 | $9.13M | Buy |
151,134
+54,447
| +56% | +$3.29M | ﹤0.01% | 2160 |
|
|
2023
Q3 | $5.51M | Buy |
96,687
+7,186
| +8% | +$410K | ﹤0.01% | 2402 |
|
|
2023
Q2 | $4.56M | Buy |
+89,501
| New | +$4.56M | ﹤0.01% | 2629 |
|
|
2023
Q1 | – | Sell |
-10,110
| Closed | -$106K | – | 5200 |
|
|
2022
Q4 | $106K | Sell |
10,110
-100
| -1% | -$1.05K | ﹤0.01% | 4664 |
|
|
2022
Q3 | $79K | Sell |
10,210
-1,575
| -13% | -$12.2K | ﹤0.01% | 4968 |
|
|
2022
Q2 | $62K | Buy |
+11,785
| New | +$62K | ﹤0.01% | 5233 |
|